Hepatocellular Carcinoma Drugs Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

 rajkumar bisen

Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy and targeted drug therapy. A majority of the HCC patients are diagnosed at the end-stage of liver dysfunction. Due to poor prognosis of the condition, mortality rate is approximately the same as the incidence rate. Therefore, early detection of the cancer is an important parameter to improve the survival of affected patients, thus aiding in growth of the global hepatocellular carcinoma drugs market.

Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1596

Market Dynamics

Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin.

Regional Dynamics

Regional segmentation of the global hepatocellular carcinoma drugs market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatocellular carcinoma drugs market over the forecast period, owing to increasing prevalence of the disease and the rising number of clinical trials undertaken by the manufacturers to address the unmet medical needs of the patients. According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with an estimated 40,000 Americans diagnosed with liver cancer in 2017 and more than 28,000 deaths are reported from the disease. Also, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma, also known as liver cancer.

Key players operating in the global hepatocellular carcinoma drugs market include Novartis Pharmaceuticals, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Celgen Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1596

Market Taxonomy

On the basis of drug class, global hepatocellular carcinoma drugs market is segmented into:

  • PD-1/PD-L1 Inhibitors

    • Nivolumab (Opdivo)

  • Tyrosine Kinase Inhibitors

    • Sorafenib (Nexavar)

    • Regorafenib (Stivarga)

On the basis of end user, the global hepatocellular carcinoma drugs market is segmented into:

  • Hospital

  • Clinics

  • Cancer Rehabilitation Centers

  • Ambulatory Surgical Centers

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Domain: Medical
Contributing Organization:
Contact Person Address: rajkumar@coherentmarketinsights.com
Posted By: rajkumar bisen and Contact rajkumar bisen
weSRCH App on Apple

Recent Press Releases

Smith Top Team Ensures Easy House Hu...

The real estate team associated with Coldwell Banker Residential Brokerage simplifies the complexities involved in house hunting to provide clients an easy and stress-free way to

22 October, 2019

Trash Rakes Market Forecast, Growth ...

Trash rakes have always been a part of hydroelectric power plants, preventing debris from entering the plant. Over the years, the trash rakes have gained increasing demand in water

18 October, 2019

Induction Sealing Machine Market For...

The induction sealing machines are used for cap sealing and threading of caps—both plastic as well as aluminum—of packaged products offered in the plastic bottles and

18 October, 2019